AAV vector-delivered gene therapy is now an established and licensed treatment for SMA with the recent approval of onasemnogene abeparvovec, which is an intravenous treatment that delivers a working copy of human SMN1 to motor neurons using AAV9 [115]. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.